Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2012 1
2013 1
2015 2
2017 1
2018 4
2019 4
2020 4
2021 8
2022 3
2023 9
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
Qin XY, Shirakami Y, Honda M, Yeh SH, Numata K, Lai YY, Li CL, Wei F, Xu Y, Imai K, Takai K, Chuma M, Komatsu N, Furutani Y, Gailhouste L, Aikata H, Chayama K, Enomoto M, Tateishi R, Kawaguchi K, Yamashita T, Kaneko S, Nagaoka K, Tanaka M, Sasaki Y, Tanaka Y, Baba H, Miura K, Ochi S, Masaki T, Kojima S, Matsuura T, Shimizu M, Chen PJ, Moriwaki H, Suzuki H. Qin XY, et al. Among authors: nagaoka k. Int J Cancer. 2024 Feb 21. doi: 10.1002/ijc.34893. Online ahead of print. Int J Cancer. 2024. PMID: 38380807
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Matoya S, Miyaki T, Kimura Y, Kusakabe A, Narahara S, Tokunaga T, Nagaoka K, Kuroyanagi K, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Suzuki T, et al. Among authors: nagaoka k. Cancer Med. 2023 Dec 22;13(1):e6876. doi: 10.1002/cam4.6876. Online ahead of print. Cancer Med. 2023. PMID: 38133557 Free PMC article.
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.
Yoshimaru Y, Nagaoka K, Tanaka K, Narahara S, Inada H, Kurano S, Tokunaga T, Iio E, Watanabe T, Setoyama H, Tateyama M, Yoshida K, Tsunoda T, Nakamura Y, Tanaka M, Sasaki Y, Tanaka Y. Yoshimaru Y, et al. Among authors: nagaoka k. Hepatol Res. 2024 May;54(5):451-464. doi: 10.1111/hepr.13995. Epub 2023 Dec 27. Hepatol Res. 2024. PMID: 38018304
Serum inducible protein 10 kDa/C-X-C motif chemokine 10 levels predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.
Nagura Y, Suzuki T, Matsuura K, Ogawa S, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Nagaoka K, Iio E, Watanabe T, Kataoka H, Tanaka Y. Nagura Y, et al. Among authors: nagaoka k. Hepatol Res. 2024 Jan;54(1):32-42. doi: 10.1111/hepr.13962. Epub 2023 Sep 6. Hepatol Res. 2024. PMID: 37638483
Molecular profiling reveals potential targets in cholangiocarcinoma.
Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK. Liu D, et al. Among authors: nagaoka k. World J Gastroenterol. 2023 Jul 7;29(25):4053-4071. doi: 10.3748/wjg.v29.i25.4053. World J Gastroenterol. 2023. PMID: 37476584 Free PMC article.
39 results